$CTXR
Citius Pharmaceuticals, Inc. Stock $ctxr

$ctxr Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000121390024067732 Filed on August 12, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$7.870M	$4.907M
YoY Change		60.38%	21.82%
% of Gross Profit
Research & Development		$2.764M	$3.765M
YoY Change		-26.58%	-22.98%
% of Gross Profit
Depreciation & Amortization		$270.00	$630.00
YoY Change		-57.14%	-13.7%
% of Gross Profit
Operating Expenses		$10.63M	$8.672M
YoY Change		22.63%	-2.74%
Operating Profit		-$10.63M	-$8.672M
YoY Change		22.63%	-2.74%
Interest Expense		$204.8K	$336.8K
YoY Change		-39.18%
% of Operating Profit
Other Income/Expense, Net		$204.8K	$336.8K
YoY Change		-39.18%
Pretax Income		-$10.43M	-$8.335M
YoY Change		25.12%	-5.96%
Income Tax		$144.0K	$144.0K
% Of Pretax Income
Net Earnings		-$10.57M	-$8.479M
YoY Change		24.7%	-4.34%
Net Earnings / Revenue
Basic Earnings Per Share			-$0.06
Diluted Earnings Per Share		-$0.06	-$0.06
COMMON SHARES
Basic Shares Outstanding	180.7M shares	180.7M shares	158.9M shares
Diluted Shares Outstanding		173.9M shares	153.8M shares

Balance Sheet

Concept	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.91M	$33.28M
YoY Change	-46.18%	-30.73%
Cash & Equivalents	$17.91M	$33.28M
Short-Term Investments
Other Short-Term Assets	$10.09M	$7.832M
YoY Change	28.88%	180.7%
Inventory
Prepaid Expenses	$10.09M	$7.832M
Receivables
Other Receivables
Total Short-Term Assets	$28.01M	$41.11M
YoY Change	-31.88%	-19.12%
LONG-TERM ASSETS
Property, Plant & Equipment		$2.010K
YoY Change		-58.39%
Goodwill	$9.347M	$9.347M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$38.06K	$38.06K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$69.08M	$69.29M
YoY Change	-0.3%	-0.27%
TOTAL ASSETS
Total Short-Term Assets	$28.01M	$41.11M
Total Long-Term Assets	$69.08M	$69.29M
Total Assets	$97.09M	$110.4M
YoY Change	-12.06%	-8.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.663M	$3.080M
YoY Change	-45.99%	82.17%
Accrued Expenses	$550.5K	$892.9K
YoY Change	-38.35%	-31.38%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.152M	$5.791M
YoY Change	-28.3%	29.81%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$84.43K	$320.0K
YoY Change	-73.62%	-39.95%
Total Long-Term Liabilities	$84.43K	$320.0K
YoY Change	-73.62%	-39.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.152M	$5.791M
Total Long-Term Liabilities	$84.43K	$320.0K
Total Liabilities	$10.81M	$12.10M
YoY Change	-10.73%	21.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$190.6M	-$152.3M
YoY Change	25.14%	25.14%
Common Stock	$180.7K	$158.9K
YoY Change	13.77%	8.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$85.68M	$97.70M
YoY Change
Total Liabilities & Shareholders Equity	$97.09M	$110.4M
YoY Change	-12.06%	-8.24%

Cashflow Statement

Concept	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$10.57M	-$8.479M
YoY Change	24.7%	-4.34%
Depreciation, Depletion And Amortization	$270.00	$630.00
YoY Change	-57.14%	-13.7%
Cash From Operating Activities	-$8.367M	-$9.583M
YoY Change	-12.68%	24.25%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	13.72M	13.80M
YoY Change	-0.58%
NET CHANGE
Cash From Operating Activities	-8.367M	-9.583M
Cash From Investing Activities
Cash From Financing Activities	13.72M	13.80M
Net Change In Cash	5.352M	4.216M
YoY Change	26.93%	-154.67%
FREE CASH FLOW
Cash From Operating Activities	-$8.367M	-$9.583M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Revenues Revenues		usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	148746002	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153775380	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	163947311	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	173856960	shares
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
	us-gaap	Revenues Revenues		usd
	us-gaap	Revenues Revenues		usd
CY2024Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2024Q2	us-gaap	Revenues Revenues		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38174
	dei	Entity Registrant Name EntityRegistrantName	Citius Pharmaceuticals, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-3425913
	dei	Entity Address Address Line1 EntityAddressAddressLine1	11 Commerce Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	First Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cranford
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07016
	dei	City Area Code CityAreaCode	(908)
	dei	Local Phone Number LocalPhoneNumber	967-6677
	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	CTXR
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	180725407	shares
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17911192	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26480928	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	10094597	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7889506	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	28005789	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	34370434	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1432	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	299932	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	454426	usd
CY2024Q2	us-gaap	Deposits Assets DepositsAssets	38062	usd
CY2023Q3	us-gaap	Deposits Assets DepositsAssets	38062	usd
CY2024Q2	ctxr	In Process Research And Development InProcessResearchAndDevelopment	59400000	usd
CY2023Q3	ctxr	In Process Research And Development InProcessResearchAndDevelopment	59400000	usd
CY2024Q2	us-gaap	Goodwill Goodwill	9346796	usd
CY2023Q3	us-gaap	Goodwill Goodwill	9346796	usd
CY2024Q2	us-gaap	Assets Assets	97090579	usd
CY2023Q3	us-gaap	Assets Assets	103611150	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1663336	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2927334	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	550485	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	476300	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1702668	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2156983	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	235581	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	218380	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4152070	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5778997	usd
CY2024Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6569800	usd
CY2023Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6137800	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	84430	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	262865	usd
CY2024Q2	us-gaap	Liabilities Liabilities	10806300	usd
CY2023Q3	us-gaap	Liabilities Liabilities	12179662	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	180725407	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	180725407	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	158857798	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	158857798	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	180725	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	158858	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	276083228	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	252903629	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-190580054	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-162231379	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	85683899	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	90831108	usd
CY2024Q2	us-gaap	Minority Interest MinorityInterest	600380	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	600380	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	86284279	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	91431488	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	97090579	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	103611150	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2763865	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3764675	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8991673	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11937045	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4808551	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3733326	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12755190	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11129463	usd
CY2024Q2	us-gaap	Share Based Compensation ShareBasedCompensation	3061763	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1174111	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9198340	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3540787	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	10634179	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	8672112	usd
	us-gaap	Operating Expenses OperatingExpenses	30945203	usd
	us-gaap	Operating Expenses OperatingExpenses	26607295	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10634179	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8672112	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30945203	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26607295	usd
CY2024Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	204843	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	336780	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	640686	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	854604	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	2387842	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	3585689	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	204843	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	336780	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3028528	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4440293	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10429336	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8335332	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27916675	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22167002	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	144000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	144000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	432000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	432000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-10573336	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8479332	usd
	us-gaap	Net Income Loss NetIncomeLoss	-28348675	usd
	us-gaap	Net Income Loss NetIncomeLoss	-22599002	usd
CY2024Q2	ctxr	Deemed Dividend On Warrant Extension DeemedDividendOnWarrantExtension	321559	usd
	ctxr	Deemed Dividend On Warrant Extension DeemedDividendOnWarrantExtension	321559	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10894895	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8479332	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28670234	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22599002	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.06
CY2023Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.06
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.17
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.15
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	173856960	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	153775380	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	163947311	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	148746002	shares
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	91431488	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	76146	usd
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3058185	usd
CY2023Q4	us-gaap	Profit Loss ProfitLoss	-9231185	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	85334634	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	98079	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3078392	usd
	us-gaap	Profit Loss ProfitLoss	-8544154	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	79966951	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	109950	usd
CY2024Q2	ctxr	Direct Offering Net Of Costs DirectOfferingNetOfCosts	1281051	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13718951	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3061763	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-10573336	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	86284279	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	103426245	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1201081	usd
CY2022Q4	us-gaap	Profit Loss ProfitLoss	-3593645	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	101033681	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	102000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	31267	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1165595	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-10526025	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	91806518	usd
CY2023Q2	ctxr	Direct Offering Net Of Costs DirectOfferingNetOfCosts	1201131	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13798870	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1174111	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-8479332	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	98300.167	usd
	us-gaap	Net Income Loss NetIncomeLoss	-28348675	usd
	us-gaap	Net Income Loss NetIncomeLoss	-22599002	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9198340	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3540787	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	284175	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	102000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	154494	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	142257	usd
	us-gaap	Depreciation Depreciation	1432	usd
	us-gaap	Depreciation Depreciation	2090	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	432000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	432000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2205091	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	4979740	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1263998	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1914289	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	74185	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-512520	usd
	ctxr	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	-454315	usd
	ctxr	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	-156806	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-161234	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-145352	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22288687	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22259997	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	13718951	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	13798870	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	31267	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13718951	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13830137	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-8569736	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-8429860	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26480928	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41711690	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17911192	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33281830	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Business</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Citius Pharmaceuticals, Inc. (“Citius Pharma,” and together with its subsidiaries, the “Company,” “we” or “us”) is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products and stem cell therapies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 30, 2016, Citius Pharma acquired Leonard-Meron Biosciences, Inc. (“LMB”) as a wholly-owned subsidiary by issuing shares of its common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 11, 2020, we formed NoveCite, Inc. (“NoveCite”), a Delaware corporation, of which we own 75% (7,500,000 shares) of the issued and outstanding capital stock (see Note 3).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 23, 2021, we formed Citius Oncology, Inc. (formerly named Citius Acquisition Corp.) (“Citius Oncology”), as a wholly-owned subsidiary in conjunction with the acquisition of LYMPHIR, which began operations in April 2022. On October 23, 2023, Citius Pharma and Citius Oncology entered into an agreement and plan of merger and reorganization with TenX Keane Acquisition, and its wholly owned subsidiary, TenX Merger Sub Inc., whereby TenX Merger Sub Inc. will merge with and into Citius Oncology, with Citius Oncology surviving as a wholly owned subsidiary of TenX Keane Acquisition. The newly combined publicly traded company is to be named “Citius Oncology, Inc.” (see Note 9). </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An inactive subsidiary, Citius Pharmaceuticals, LLC, was dissolved on December 29, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In-process research and development (“IPR&D”) consists of (i) the $19,400,000 acquisition value of LMB’s drug candidate Mino-Lok®, which is an antibiotic solution used to treat catheter-related bloodstream infections and is expected to be amortized on a straight-line basis over a period of eight years commencing upon revenue generation, and (ii) the $40,000,000 acquisition value of the exclusive license for LYMPHIR (denileukin diftitox), which is a late-stage oncology immunotherapy for the treatment of cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma, and is expected to be amortized on a straight-line basis over a period of twelve years commencing upon revenue generation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill of $9,346,796 represents the value of LMB’s industry relationships and its assembled workforce. Goodwill will not be amortized but will be tested at least annually for impairment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since our inception, we have devoted substantially all our efforts to business planning, research and development, recruiting management and technical staff, and raising capital. We are subject to a number of risks common to companies in the pharmaceutical industry including, but not limited to, risks related to the development by Citius Pharma or its competitors of research and development stage products, regulatory approval and market acceptance of its products, competition from larger companies, dependence on key personnel, dependence on key suppliers and strategic partners, the Company’s ability to obtain additional financing and the Company’s compliance with governmental and other regulations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation and Summary of Significant Accounting Policies</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Basis of Preparation </i>— The accompanying unaudited condensed consolidated financial statements include the operations of Citius Pharmaceuticals, Inc., and its wholly-owned subsidiaries, LMB and Citius Oncology, and its majority-owned subsidiary NoveCite. NoveCite began operations in October 2020 and Citius Oncology began operations in April 2022. All significant inter-company balances and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state the condensed consolidated financial position of the Company as of June 30, 2024, and the results of its operations and cash flows for the three- and nine-month periods ended June 30, 2024 and 2023. The operating results for the three- and nine-month periods ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending September 30, 2024. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2023 filed with the Securities and Exchange Commission (“SEC”) on December 29, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Use of Estimates </i>— Our accounting principles require our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting period. Estimates having relatively higher significance include the accounting for in-process research and development and goodwill impairment, stock-based compensation, valuation of warrants, and income taxes. Actual results could differ from those estimates and changes in estimates may occur.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Basic and Diluted Net Loss per Common Share</i> — Basic and diluted net loss per common share applicable to common stockholders is computed by dividing net loss applicable to common stockholders in each period by the weighted average number of shares of common stock outstanding during such period. For the periods presented, common stock equivalents, consisting of stock options and warrants, were not included in the calculation of the diluted loss per share because they were anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recently Issued Accounting Standards </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than as disclosed in our Form 10-K, we are not aware of any other recently issued accounting standards not yet adopted that may have a material impact on our financial statements.</p>
CY2020Q3	ctxr	Capital Stock Issued CapitalStockIssued	7500000	shares
CY2020Q3	ctxr	Capital Stock Outstanding CapitalStockOutstanding	7500000	shares
CY2024Q2	us-gaap	Goodwill Goodwill	9346796	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Use of Estimates </i>— Our accounting principles require our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting period. Estimates having relatively higher significance include the accounting for in-process research and development and goodwill impairment, stock-based compensation, valuation of warrants, and income taxes. Actual results could differ from those estimates and changes in estimates may occur.</p>
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22288687	usd
CY2024Q2	ctxr	Working Capital WorkingCapital	23850000	usd
CY2024Q2	us-gaap	Prepaid Insurance PrepaidInsurance	87782	usd
CY2023Q3	us-gaap	Prepaid Insurance PrepaidInsurance	154611	usd
	us-gaap	Payments For Advance To Affiliate PaymentsForAdvanceToAffiliate	10006815	usd
CY2023Q3	us-gaap	Payments For Advance To Affiliate PaymentsForAdvanceToAffiliate	7734895	usd
CY2023Q2	ctxr	Direct Offering Common Shares DirectOfferingCommonShares	12500001	shares
CY2023Q2	ctxr	Purchase Price PurchasePrice	1.2
CY2023Q2	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	15000001	usd
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.75
	us-gaap	Deferred Compensation Arrangement With Individual Maximum Contractual Term1 DeferredCompensationArrangementWithIndividualMaximumContractualTerm1	P10Y
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13305171	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.79
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M28D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	56203	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4160000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.7
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	53114	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.02
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	493283	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.59
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16918774	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.54
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M25D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	750	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	9192107	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.91
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y2M15D
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	750	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Other Share Increase Decrease In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice	0.69
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Other Share Increase Decrease In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice	0.53
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.25
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1174111	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9198340	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3651795	usd
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	73633421	shares
	us-gaap	Dividends Dividends	321559	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16918774	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	7575000	shares
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	73633421	shares
CY2024Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	98127195	shares
	us-gaap	Operating Lease Cost OperatingLeaseCost	179117	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	179118	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	3732	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	3567	usd
	us-gaap	Lease Cost LeaseCost	182849	usd
	us-gaap	Lease Cost LeaseCost	182685	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y3M18D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	63167	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	253883	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	21460	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	338510	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	18499	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	320011	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	299932	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	454426	usd
CY2024Q2	ctxr	Operating Lease Assets OperatingLeaseAssets	299932	usd
CY2023Q3	ctxr	Operating Lease Assets OperatingLeaseAssets	454426	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	235581	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	218380	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	84430	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	262865	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	320011	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	481245	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	24623	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	36861	usd
	us-gaap	Discontinued Operation Amount Of Adjustment To Prior Period Gain Loss On Disposal Before Income Tax DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalBeforeIncomeTax	2387842	usd
	us-gaap	Discontinued Operation Amount Of Adjustment To Prior Period Gain Loss On Disposal Before Income Tax DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalBeforeIncomeTax	3585689	usd
CY2023Q3	us-gaap	Auction Market Preferred Securities Stock Series Par Value Per Share AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare	1
CY2024Q1	us-gaap	Auction Market Preferred Securities Stock Series Par Value Per Share AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare	1
CY2024Q2	us-gaap	Equity Issued In Business Combination Fair Value Disclosure EquityIssuedInBusinessCombinationFairValueDisclosure	67500000	usd
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	ctxr	Deemed Dividend On Warrant Extension DeemedDividendOnWarrantExtension		usd
	ctxr	Deemed Dividend On Warrant Extension DeemedDividendOnWarrantExtension		usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.06
CY2023Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.06
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.15
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.17
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001506251

Files In Submission

Name	View Source	Status
ctxr-20240630_cal.xml	Edgar Link	unprocessable
0001213900-24-067732-index-headers.html	Edgar Link	pending
0001213900-24-067732-index.html	Edgar Link	pending
0001213900-24-067732.txt	Edgar Link	pending
0001213900-24-067732-xbrl.zip	Edgar Link	pending
ctxr-20240630.xsd	Edgar Link	pending
ea0210893-10q_citius.htm	Edgar Link	pending
ea021089301ex1-1_citius.htm	Edgar Link	pending
ea021089301ex31-1_citius.htm	Edgar Link	pending
ea021089301ex31-2_citius.htm	Edgar Link	pending
ea021089301ex32-1_citius.htm	Edgar Link	pending
ea021089301ex5-1_citius.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
ctxr-20240630_def.xml	Edgar Link	unprocessable
ctxr-20240630_pre.xml	Edgar Link	unprocessable
ctxr-20240630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0210893-10q_citius_htm.xml	Edgar Link	completed
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTXR
Citius Pharmaceuticals, Inc. Stock $ctxr

2024 Q3 Form 10-Q Financial Statement

#000121390024067732 Filed on August 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTXR Citius Pharmaceuticals, Inc. Stock $ctxr

2024 Q3 Form 10-Q Financial Statement

#000121390024067732 Filed on August 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTXR
Citius Pharmaceuticals, Inc. Stock $ctxr